^
Association details:
| Biomarker: | PLCG2 mutation |
|---|---|
| Cancer: | Follicular Lymphoma |
| Regimen: | (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
MUTATIONAL PROFILE IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA AND CORRELATION WITH OUTCOME AFTER TREATMENT WITH INMUNOCHEMOTHERAPY
Published date:
06/12/2020
Excerpt:
Among genes frequently mutated, we observed an association with worse PFS in cases bearing mutations in KMT2D, BCL7A and ARID1B…Despite being infrequent, PLCG2 and TNFA1P3 mutated cases showed a statistically significant dismal outcome…
